

Press Release
Västra Frölunda, Sweden, February 20, 2009

ARTIMPLANT YEAR-END REPORT JANUARY – DECEMBER 2008

- **Net revenue for the fourth quarter amounted to SEK 4.6 million (5.0) and for January-December to SEK 12.1 million (16.3)***
- **The net loss for the fourth quarter totaled SEK 6.0 million (2.1) and for January-December SEK 22.6 million (13.5)**
- **Earnings per share for the fourth quarter amounted to SEK -0.10 (-0.04) and for January-December SEK -0.38 (-0.23)**
- **Sales of Artelon[®] Spacer to end-customers totaled approximately 3,500 (3,900) units, of which 900 (1,100) were during the fourth quarter**
- **Sales of Artelon[®] Tissue Reinforcement to end-customers totaled approximately 1,000 (600) units, of which 300 (200) were during the fourth quarter**
- **An exclusive distributor agreement for the USA regarding Artelon[®] CCL for cruciate ligament reconstruction in dogs has been signed with BioMedtrix**
- **Proof-of-concept animal study commenced for treatment with Artelon[®] of osteoarthritis in the knee**
- **Over 11,000 patients have been treated with Artelon[®] implants up to and including December 2008**

EVENTS AFTER THE PERIOD-END

- **Spacer agreements with Small Bone Innovations have been made non-exclusive and Artimplant's margin per unit sold has been increased significantly**

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will hold a telephone conference by reason of this report on February 20, 2009 at 11 am (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For additional information, please contact:

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html



Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
SWEDEN

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Reg. No. 556404-8394

Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[®], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the NASDAQ OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on February 20, 2009 at 8:45 am (GMT+1).